Evidence map›Paper›PMID 41560802›Full record

ArticleMaterials today. Bio2026

Radioactive hydrogel with NETs degradation capacity for the boosted tumor radio-immunotherapy.

Bingshu Zheng, Zimeng Xu, Ying Zhang, Hengyu Zhang, Chunfeng Sun, Xuan Yi, Hailin Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bingshu ZhengDepartment of Nuclear Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
Zimeng XuSchool of Pharmacy, Jiangsu Key Laboratory of Inflammation and Molecular Drug Targets, Nantong University, Nantong, Jiangsu, 226001, China.
Ying ZhangDepartment of Vascular Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226601, China.
Hengyu ZhangSchool of Pharmacy, Jiangsu Key Laboratory of Inflammation and Molecular Drug Targets, Nantong University, Nantong, Jiangsu, 226001, China.
Chunfeng SunDepartment of Nuclear Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.
Xuan YiSchool of Pharmacy, Jiangsu Key Laboratory of Inflammation and Molecular Drug Targets, Nantong University, Nantong, Jiangsu, 226001, China.
Hailin ZhouResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioisotope therapy is a clinically effective cancer treatment. However, its therapeutic efficacy is limited by the short retention time of radioisotopes and multiple tumor radiation resistance mechanisms in tumor. Neutrophil extracellular traps (NETs), whose formation is enhanced under ionizing radiation exposure, can reduce tumor radiation response and interfere with the anti-tumor effects of immune cells. Herein, we labeled carboxymethyl chitosan methacryloyl (CMCSMA) with iodine-131 (

Indexed as

BrachytherapyCarboxymethyl chitosanHydrogelImmunotherapyNETs

Identifiers

PMID41560802
PMCPMC12813226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.